ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Japanese companies Astellas Pharma and PeptiDream have announced a collaboration to discover new protein degraders for two targets of Astellas’s choosing and potentially another three. PeptiDream boasts a discovery platform for macrocyclic peptide drugs that is licensed from the University of Tokyo. On top of the $21 million cash sum PeptiDream will receive from the deal, the company is also eligible for royalties and $150 million in milestones per target.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter